Genmab A/S Files 6-K, Incorporates into S-8 Filings
Ticker: GNMSF · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, registration-statement, compliance
TL;DR
Genmab 6-K filed March 21, 2024, updates S-8 filings - standard procedure.
AI Summary
Genmab A/S filed a Form 6-K on March 21, 2024, to report information as a foreign private issuer. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing ensures that Genmab's ongoing registration statements for its equity incentive plans are kept up-to-date with current information, which is crucial for compliance and investor confidence.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new financial or operational information that would typically pose a risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What type of filing is this Form 6-K?
This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on March 21, 2024.
What is the primary purpose of this filing?
The primary purpose is to furnish information to the SEC and to be incorporated by reference into Genmab A/S's registration statements on Form S-8.
Which registration statements are being updated by this filing?
This filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-03-21 15:28:21
Filing Documents
- tmb-20240321x6k.htm (6-K) — 19KB
- tmb-20240321xex3d1.htm (EX-3.1) — 385KB
- 0001558370-24-003696.txt ( ) — 405KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: March 21, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 3.1 Articles of Association